Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer

Abstract Background There is little evidence of abiraterone acetate (AA) plus prednisone for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). In this study, we conducted a comparative analysis of real‐world survival outcomes between AA plus prednisone and enzalutamide (Enz...

Full description

Bibliographic Details
Main Authors: Takuya Tsujino, Satoshi Tokushige, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Takaya Ohno, Keita Nakamori, Ryoichi Maenosono, Kazuki Nishimura, Shogo Yamazaki, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Fumihiko Urabe, Shunsuke Tsuzuki, Kosuke Iwatani, Shutaro Yamamoto, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Cancer Medicine
Subjects:
abiraterone acetate
androgen receptor signaling inhibitor
castration‐resistant prostate cancer
enzalutamide
nonmetastatic castration‐resistant prostate cancer
Online Access:https://doi.org/10.1002/cam4.6536

Internet

https://doi.org/10.1002/cam4.6536

Similar Items